Primary Progressive Multiple Sclerosis Treatment Market

Primary Progressive Multiple Sclerosis Treatment Market (Drug Type: Approved Drugs and Pipeline Drugs; and Distribution Channel: Retail Pharmacies, E-commerce, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Global Primary Progressive Multiple Sclerosis Treatment Market Outlook 2031

  • The industry was valued at US$ 828.4 Mn in 2021
  • It is projected to advance at a CAGR of 14.7% from 2022 to 2031 ad reach more than US$ 3.2 Bn by the end of 2031

Analysts’ Viewpoint

Increase in geriatric population and rise in prevalence of primary progressive multiple sclerosis (PPMS) across the globe are key factors that are positively impacting market statistics. Governments of developed and developing countries are taking initiatives to raise public awareness about the various available treatment options for multiple sclerosis. This is resulting in market expansion.

Improvements in healthcare infrastructure carried out by government and non-governmental organizations are expected to propel market growth in the near future. Key players are investing significantly in R&D activities to grab lucrative primary progressive multiple sclerosis treatment market opportunities.

Primary Progressive Multiple Sclerosis Treatment Market

Global PPMS Treatment Market Introduction

Primary progressive multiple sclerosis is a neurodegenerative disease, wherein a person’s immunity system adversely affects the outer protective covering of nerve cells in the brain called myelin. The nerves in and around the brain and spinal cord get damaged due to the disease. Vision-related nerves may also be affected.

PPMS is usually observed in people aged between 35 years and 40 years. Early symptoms of the disease are often subtle. These include difficulty in walking that develops over time. Initially, the affected individual experiences very little or no relapse of the disease. The disability increases gradually. Symptoms may appear to remain stable for protracted periods of time.

Request a sample to get extensive insights into the Primary Progressive Multiple Sclerosis Treatment Market

Rise in Prevalence of Primary Progressive Multiple Sclerosis Across Globe

Growth in prevalence of primary progressive multiple sclerosis is significantly impacting market development. Women are more susceptible to multiple sclerosis than men. Rise in number of people with multiple sclerosis is expected to boost the demand for drugs and medical attention related to the disease during the forecast period. Furthermore, the effectiveness of drugs and quick advances in MS therapy are anticipated to fuel the market in the near future.

According to a study carried out by the National Multiple Sclerosis Society (NMSS) in September 2020, there were 2.8 million people living with multiple sclerosis (MS) globally. This suggests that someone somewhere in the world is diagnosed with multiple sclerosis every five minutes. Thus, around 0.5 million people in the world are estimated to be living with PMSS. Hence, rise in prevalence of PPMS is projected to augment the global market share during the forecast period.

Increase in Healthcare Expenditure to Drive Primary Progressive Multiple Sclerosis Treatment Market

Rise in healthcare expenditure, which aids in the improvement of related infrastructure, is a crucial factor influencing market expansion. According to the primary progressive multiple sclerosis treatment market forecast report, growth in awareness about multiple sclerosis due to initiatives by various public and private organizations is likely to fuel the industry during the forecast period. Increase in geriatric population and constantly evolving lifestyles of the people are also likely to accelerate market growth.

Request a custom report on Primary Progressive Multiple Sclerosis Treatment Market

Ongoing Research and Development Activities in PPMS Treatment

Primary progressive multiple sclerosis treatment market growth can be ascribed to the increase in emphasis on research and development activities to develop innovative drugs by major players. Currently, Roche's OCREVUS (Ocrelizumab) is available in the market. However, its efficacy is limited. Currently, 19 products are under clinical development; of these, three are in phase 3 of clinical trials.

Players in the market are increasing their R&D activities for the treatment of the PPMS disease. Several governments and private organizations are funding a number of schemes and programs to provide support to improve the quality of life of individuals affected by the disease.

Surge in Demand for Approved Drugs to Treat Primary Progressive Multiple Sclerosis

As per the market segmentation, the industry has been divided into approved drugs and pipeline drugs based on drug type. Currently, Roche’s Ocrelizumab with the brand name OCREVUS is the only drug available in the market for the treatment of PPMS. Hence, the approved drugs segment is anticipated to dominate during the forecast period.

Pipeline drugs are expected to obtain approval over the next few years. More than 15 drugs are under clinical trials in phases two and three. Thus, the pipeline drugs segment is anticipated to grow at the highest CAGR during the forecast period, owing to the increase in investment in R&D by companies across the globe.

Growth in Number of Retail Pharmacies

Based on distribution channel, the business has been segmented into retail pharmacies, e-commerce, and others. The retail pharmacies segment is projected to dominate during the forecast period, primarily due to the availability of favorable health reimbursement policies. Increase in number of retail pharmacies supported by government and private organizations is contributing to market progress.

The e-commerce segment is likely to grow at the highest CAGR during the forecast period, owing to the rise in number of online portals distributing prescription drugs across the world. Primary progressive multiple sclerosis treatment industry demand is increasing, with growth in online home delivery of pharmaceuticals.

Regional Outlook of Primary Progressive Multiple Sclerosis Treatment Industry

North America’s market size is anticipated to increase during the forecast period. Rise in prevalence of PPMS in the U.S. and increase in demand for therapeutic drugs for the treatment of PPMS are the key factors fueling market development in the region.

Asia Pacific is projected to register the highest CAGR during the forecast period, owing to the rise in awareness about the treatment for primary progressive multiple sclerosis among the population. Improvement in healthcare infrastructure in economies such as India and China is also contributing to market expansion in the region.

Analysis of Key Players

The global market is fragmented, with the presence of a large number of prominent players controlling majority of the share. Some of the major companies in PPMS treatment market across the globe are F. Hoffmann-La Roche Ltd., Sanofi, Mapi Pharma Ltd., Atara Biotherapeutics, Takeda Pharmaceuticals International, Inc., AB Science, and Mallinckrodt. These players are engaged in research and development activities and have drugs in the pipeline for clinical trials.

Key Developments in Primary Progressive Multiple Sclerosis Treatment Market

  • In November 2022, the research team of the International Progressive MS Alliance produced significant results regarding the impact of shortening the length of clinical trials and reducing the number of people needed to test therapies for progressive MS. International Progressive MS Alliance is a global collaboration of MS organizations, scientists, health professionals, the pharmaceutical industry, foundations, donors, and patients with PPMS working together to support the development of effective treatment for the disease in order to improve the quality of life of the affected individuals.
  • In March 2017, the U.S. Food and Drug Administration approved the Ocrelizumab drug sold under the brand name OCREVUS for the treatment of patients suffering from multiple sclerosis as well as PPMS. This is the first primary progressive MS medication approved by the FDA. OCREVUS is an intravenous infusion administered by a medical expert.

The market report profiles key players in terms of product portfolio, recent developments, company overview, financial overview, business strategies, and business segments.

Market Snapshot

Attribute

Detail

Market Size Value in 2021

US$ 828.4 Mn

Market Forecast Value in 2031

More than US$ 3.2 Bn

Growth Rate (CAGR) 2022-2031

14.7%

Forecast Period

2022–2031

Historical Data Available for

2017–2021

Quantitative Units

US$ Mn/Bn for Value

Market Analysis

It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, pipeline analysis and key trend analysis.

Competition Landscape

  • Market share analysis by company (2021)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • By Drug Type
    • Approved Drugs
    • Pipeline Drugs
  • By Distribution Channel
    • Retail Pharmacies
    • E-commerce
    • Others

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • F. Hoffmann-La Roche Ltd.
  • Sanofi
  • Mapi Pharma Ltd.
  • Atara Biotherapeutics
  • Takeda Pharmaceuticals International, Inc.
  • AB Science
  • Mallinckrodt

Customization Scope

Available upon request

Pricing

Available upon request

Frequently Asked Questions

How big was the global primary progressive multiple sclerosis treatment market in 2021?

It was valued at US$ 828.4 Mn in 2021

How much worth would the industry be in 2031?

It is projected to reach more than US$ 3.2 Bn by 2031

What will be the CAGR during the forecast period?

The CAGR is anticipated to be 14.7% during the forecast period

What was the CAGR during the period of 2017 to 2021?

The CAGR stood at 57.8% from 2017 to 2021

Which region is expected to hold major share during the forecast period?

North America is expected to hold major share during the forecast period

Who are the prominent players in the global primary progressive multiple sclerosis treatment market?

F. Hoffmann-La Roche Ltd., Sanofi, Mapi Pharma Ltd., Atara Biotherapeutics, Takeda Pharmaceuticals International, Inc., AB Science, and Mallinckrodt

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Primary Progressive Multiple Sclerosis Treatment Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Definition

            4.1.2. Industry Evolution/Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecasts, 2017 - 2031

            4.4.1. Market Revenue Projections (US$ Mn)

        4.5. Porter’s Five Force Analysis

    5. Key Insights

        5.1. Key Mergers & Acquisitions

        5.2. Pipeline Analysis

        5.3. Disease Prevalence & Incidence Rate globally with key countries

        5.4. Key Product/Brand Analysis

        5.5. Major Research Institutes Involved

        5.6. COVID-19 Pandemic Impact on Industry (Value Chain and Short / Mid / Long Term Impact)

    6. Global Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecasts, By Drug Type

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Market Value Forecast By Drug Type, 2017 - 2031

            6.3.1. Approved Drugs

            6.3.2. Pipeline Drugs

        6.4. Market Attractiveness By Drug Type

    7. Global Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecasts, By Distribution Channel

        7.1. Introduction & Definition

        7.2. Key Findings/Developments

        7.3. Market Value Forecast By Distribution Channel, 2017 - 2031

            7.3.1. Retail Pharmacies

            7.3.2. E-commerce

            7.3.3. Others

        7.4. Market Attractiveness By Distribution Channel

    8. Global Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecasts, By Region

        8.1. Key Findings

        8.2. Market Value Forecast By Region

            8.2.1. North America

            8.2.2. Europe

            8.2.3. Asia Pacific

            8.2.4. Latin America

            8.2.5. Middle East & Africa

        8.3. Market Attractiveness By Country/Region

    9. North America Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast

        9.1. Introduction

            9.1.1. Key Findings

        9.2. Market Value Forecast By Drug Type, 2017 - 2031

            9.2.1. Approved Drugs

            9.2.2. Pipeline Drugs

        9.3. Market Value Forecast By Distribution Channel, 2017 - 2031

            9.3.1. Retail Pharmacies

            9.3.2. E-commerce

            9.3.3. Others

        9.4. Market Value Forecast By Country, 2017 - 2031

            9.4.1. U.S.

            9.4.2. Canada

        9.5. Market Attractiveness Analysis

            9.5.1. By Drug Type

            9.5.2. By Distribution Channel

            9.5.3. By Country

    10. Europe Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Market Value Forecast By Drug Type, 2017 - 2031

            10.2.1. Approved Drugs

            10.2.2. Pipeline Drugs

        10.3. Market Value Forecast By Distribution Channel, 2017 - 2031

            10.3.1. Retail Pharmacies

            10.3.2. E-commerce

            10.3.3. Others

        10.4. Market Value Forecast By Country, 2017 - 2031

            10.4.1. Germany

            10.4.2. U.K.

            10.4.3. France

            10.4.4. Spain

            10.4.5. Italy

            10.4.6. Rest of Europe

        10.5. Market Attractiveness Analysis

            10.5.1. By Drug Type

            10.5.2. By Distribution Channel

            10.5.3. By Country

    11. Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast By Drug Type, 2017 - 2031

            11.2.1. Approved Drugs

            11.2.2. Pipeline Drugs

        11.3. Market Value Forecast By Distribution Channel, 2017 - 2031

            11.3.1. Retail Pharmacies

            11.3.2. E-commerce

            11.3.3. Others

        11.4. Market Value Forecast By Country, 2017 - 2031

            11.4.1. China

            11.4.2. Japan

            11.4.3. India

            11.4.4. Australia & New Zealand

            11.4.5. Rest of Asia Pacific

        11.5. Market Attractiveness Analysis

            11.5.1. By Drug Type

            11.5.2. By Distribution Channel

            11.5.3. By Country

    12. Latin America Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast By Drug Type, 2017 - 2031

            12.2.1. Approved Drugs

            12.2.2. Pipeline Drugs

        12.3. Market Value Forecast By Distribution Channel, 2017 - 2031

            12.3.1. Retail Pharmacies

            12.3.2. E-commerce

            12.3.3. Others

        12.4. Market Value Forecast By Country, 2017 - 2031

            12.4.1. Brazil

            12.4.2. Mexico

            12.4.3. Rest of Latin America

        12.5. Market Attractiveness Analysis

            12.5.1. By Drug Type

            12.5.2. By Distribution Channel

            12.5.3. By Country

    13. Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast By Drug Type, 2017 - 2031

            13.2.1. Approved Drugs

            13.2.2. Pipeline Drugs

        13.3. Market Value Forecast By Distribution Channel, 2017 - 2031

            13.3.1. Retail Pharmacies

            13.3.2. E-commerce

            13.3.3. Others

        13.4. Market Value Forecast By Country, 2017 - 2031

            13.4.1. GCC Countries

            13.4.2. South Africa

            13.4.3. Rest of Middle East & Africa

        13.5. Market Attractiveness Analysis

            13.5.1. By Drug Type

            13.5.2. By Distribution Channel

            13.5.3. By Country

    14. Competition Landscape

        14.1. Market Player – Competition Matrix (By Tier and Size of Companies)

        14.2. Market Share Analysis By Company (2021)

        14.3. Company Profiles

            14.3.1. F. Hoffmann-La Roche Ltd.

                14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.1.2. Company Financials

                14.3.1.3. Growth Strategies

                14.3.1.4. SWOT Analysis

            14.3.2. Sanofi

                14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.2.2. Company Financials

                14.3.2.3. Growth Strategies

                14.3.2.4. SWOT Analysis

            14.3.3. Mapi Pharma Ltd.

                14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.3.2. Company Financials

                14.3.3.3. Growth Strategies

                14.3.3.4. SWOT Analysis

            14.3.4. Atara Biotherapeutics

                14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.4.2. Company Financials

                14.3.4.3. Growth Strategies

                14.3.4.4. SWOT Analysis

            14.3.5. Takeda Pharmaceuticals International, Inc.

                14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.5.2. Company Financials

                14.3.5.3. Growth Strategies

                14.3.5.4. SWOT Analysis

            14.3.6. AB Science

                14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.6.2. Company Financials

                14.3.6.3. Growth Strategies

                14.3.6.4. SWOT Analysis

            14.3.7. Mallinckrodt

                14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.7.2. Company Financials

                14.3.7.3. Growth Strategies

                14.3.7.4. SWOT Analysis

    List of Tables

    Table 01: Global Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

    Table 02: Global Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 03: Global Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2031

    Table 04: North America Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

    Table 05: North America Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 06: North America Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2031

    Table 07: Europe Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

    Table 08: Europe Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 09: Europe Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 10: Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

    Table 11: Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 12: Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 13: Latin America Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

    Table 14: Latin America Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 15: Latin America Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 16: Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

    Table 17: Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 18: Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    List of Figures

    Figure 01: Global Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, 2017–2031

    Figure 02: Global Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Drug Type, 2021 and 2031

    Figure 03: Global Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Drug Type, 2022–2031

    Figure 04: Global Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Distribution Channel, 2021 and 2031

    Figure 05: Global Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031

    Figure 06: Global Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Region, 2021 and 2031

    Figure 07: Global Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Region, 2022–2031

    Figure 08: North America Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, 2017–2031

    Figure 09: North America Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Drug Type, 2021 and 2031

    Figure 10: North America Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Drug Type, 2022–2031

    Figure 11: North America Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Distribution Channel, 2021 and 2031

    Figure 12: North America Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031

    Figure 13: North America Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Country, 2021 and 2031

    Figure 14: North America Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Country, 2022–2031

    Figure 15: Europe Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, 2017–2031

    Figure 16: Europe Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Drug Type, 2021 and 2031

    Figure 17: Europe Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Drug Type, 2022–2031

    Figure 18: Europe Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Distribution Channel, 2021 and 2031

    Figure 19: Europe Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031

    Figure 20: Europe Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031

    Figure 21: Europe Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    Figure 22: Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, 2017–2031

    Figure 23: Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Drug Type, 2021 and 2031

    Figure 24: Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Drug Type, 2022–2031

    Figure 25: Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Distribution Channel, 2021 and 2031

    Figure 26: Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031

    Figure 27: Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031

    Figure 28: Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    Figure 29: Latin America Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, 2017–2031

    Figure 30: Latin America Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Drug Type, 2021 and 2031

    Figure 31: Latin America Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Drug Type, 2022–2031

    Figure 32: Latin America Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Distribution Channel, 2021 and 2031

    Figure 33: Latin America Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031

    Figure 34: Latin America Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031

    Figure 35: Latin America Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    Figure 36: Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, 2017–2031

    Figure 37: Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Drug Type, 2021 and 2031

    Figure 38: Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Drug Type, 2022–2031

    Figure 39: Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Distribution Channel, 2021 and 2031

    Figure 40: Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031

    Figure 41: Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031

    Figure 42: Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    Figure 43: Global Primary Progressive Multiple Sclerosis Treatment Market Share Analysis/Ranking, by Company, 2021

Copyright © Transparency Market Research, Inc. All Rights reserved